EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 33 / Numéro 10 (Octobre 2017) Med Sci (Paris), 33 10 (2017) 891-897 Références
Accès gratuit
Numéro
Med Sci (Paris)
Volume 33, Numéro 10, Octobre 2017
Page(s) 891 - 897
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20173310022
Publié en ligne 10 octobre 2017
  1. PREVAIL II writing group; Multi-national PREVAIL II study team, Davey RT Jr, Dodd L, Proschan MA, et al. A randomized, controlled trial of ZMapp for Ebola virus infection. N Engl J Med 2016; 375 : 1448–1456. [Google Scholar]
  2. Fassin D. Santé globale, un nouveau concept ? Quelques enseignements de l’épidémie à virus Ébola. Med Sci (Paris) 2015 ; 31 : 463–464. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  3. Briand S, Bertherat E, Cox P, et al. The international Ebola emergency. New Engl J Med 2014 ; 371 : 1180–1183. [CrossRef] [Google Scholar]
  4. Krech R, Kieny MP. The 2014 Ebola outbreak: ethical use of unregistered interventions. Bull World Health Organ 2014 ; 92 : 622. [CrossRef] [PubMed] [Google Scholar]
  5. Yazdanpanah Y, Arribas JR, Malvy D. Treatment of Ebola virus disease. Intensive Care Med 2015 ; 41 : 115–117. [CrossRef] [PubMed] [Google Scholar]
  6. Zeitlin L, Whaley KJ, Olinger GG, et al. Antibody therapeutics for Ebola virus disease. Curr Opin Virol 2016 ; 17 : 45–49. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  7. Jahrling P, Geisbert T, Geisbert J, et al. Evaluation of immune globulin and recombinant interferon-α2b for treatment of experimental Ebola virus infections. J Infect Dis 1999 ; 179 (suppl 1) : S224–S234. [CrossRef] [PubMed] [Google Scholar]
  8. van Griensven J, Edwards T, de Lamballerie X, et al. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med 2016 ; 374 : 33–42. [Google Scholar]
  9. Qiu X, Wong G, Audet J, et al. Reversion of advanced Ebola virus disease in non-human primates with ZMapp. Nature 2014 ; 514 : 47–53. [CrossRef] [PubMed] [Google Scholar]
  10. Malvy D. Science in a crisis. Medical countermeasures in Ebola virus disease, 2016: lessons learned and perspectives. Bull Soc Pathol Exot 2016 ; 109 : 262–271. [CrossRef] [PubMed] [Google Scholar]
  11. Dodd LE, Proschan MA, Neuhaus J, et al. Design of a randomized controlled trial for Ebola virus disease medical countermeasures: PREVAIL II, the Ebola MCM Study. J Infect Dis 2016 ; 213 : 1906–1913. [CrossRef] [PubMed] [Google Scholar]
  12. Henao-Restrepo AM, Camacho A, Longini IM, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola ça suffit !). Lancet 2017 ; 389 : 505–518. [CrossRef] [PubMed] [Google Scholar]
  13. Sissoko D, Laouénan C, Folkesson E, et al. Experimental treatment of favipiravir for Ebola virus disease (the JIKI trial): a historically-controlled, single arm proof-of concept trial in Guinea. PLoS Med 2016 ; 13 : e1001967. [Google Scholar]
  14. Duraffour S, Malvy D, Sissoko D. How to treat Ebola virus infections? A lesson from the field. Curr Opin Virol 2017 ; 24 : 9–15. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  15. Dunning J, Sahr F, Rojek A, et al. Experimental treatment of Ebola virus disease with TKM-130803: A single-arm Phase 2 clinical trial. PLoS Med 2016 ; 13 : e1001997. [Google Scholar]
  16. Dunning J, Kennedy SB, Antierens A, et al. Experimental treatment of Ebola virus disease with brincidofovir. PLoS One 2016 ; 11 : e0162199. [CrossRef] [PubMed] [Google Scholar]
  17. Warren TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 2016 ; 531 : 381–385. [CrossRef] [PubMed] [Google Scholar]
  18. Nguyen TH, Guedj J, Anglaret X, et al. Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. PLoS Negl Trop Dis 2017 ; 11 : e0005389. [CrossRef] [PubMed] [Google Scholar]
  19. Sissoko D, Duraffour S, Kerber R, et al. Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling study. Lancet Glob Health 2017 ; 5 : e80–e88. [Google Scholar]
  20. Ethical issues related to study design for trials on therapeutics for Ebola Virus Disease. 2014. Report of the WHO ethics working group meeting. 20–21 October 2014. Geneva : World health Organization, 2014. http://apps.who.int/iris/bitstream/10665/137509/1/WHO_HIS_KER_GHE_14.2_eng.pdf. [Google Scholar]
  21. Diallo B, Sissoko D, Loman NJ, et al. Resurgence of Ebola virus disease in Guinea linked to a survivor with virus persistence in seminal fluid for more than 500 days. Clin Infect Dis 2016 ; 63 : 1353–1356. [CrossRef] [PubMed] [Google Scholar]
  22. Maehira Y, Kurosaki Y, Saito T, et al. Responding to ever-changing epidemiological dynamics of Ebola virus disease. BMJ Global Health 2016 ; 1 : e000180. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.